A1107T Oncodesign SA

Etude de l'AG du 29/06/2017

Da façon générale, la communication de la société est plutôt basique, voire lacunaire puisque la description du conseil est assez parcellaire (absence de communication des dates de début et de fin de mandats), de même que la communication des honoraires des commissaires aux comptes (la société se contente de communiquer un montant global sans en préciser la répartition entre chacun des commissaires ou la répartition entre les différents postes de facturation).

De plus, la communication sur les rémunérations des dirigeants est nulle : la société se contente d'indique que communiquer les montants des rémunérations des dirigeants (information figurant normalement dans les Transactions avec les parties liées) "aboutirait à communiquer un montant individuel".

14/06/2017
15 pages
FR

Research Provider

Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.

Proxinvest main services are :

  • ​Proxy reports
  • Definition and monitoring of client customized voting guidelines
  • Corporate Governance Data and Rating
  • Thematic research
  • Engagement support

Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.

Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.

As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide. 

Read more

Underlying

Health Care - France

Oncodesign SA is a France-based company that discovers and develops therapies against cancer. The Company's services include target identification, validation and cellular screens; preclinical research, in vivo screening and pharmacology; molecular pharmacology and biomarkers, pharmaco-imaging and immunology, among others. Its activities include preclinical evaluation services and discovery operations. The Company's technologies include Predict, Chi-Mice, Pharm'Image and Nanocyclix. Its technological platform offers solutions for pharmaceutical and biotechnology companies.

Read more

ResearchPool Subscriptions

Get the most out of your insights

Get in touch